Balancing risks and therapeutic benefits. About adjuvant tamoxifen treatment for breast cancer patients

被引:7
|
作者
Sarradon-Eck, Aline [1 ]
Pellegrini, Isabelle [2 ]
机构
[1] MMSH, Ctr Norbert Elias, Equipe GReCSS PAS Anthropol Sante, F-130949 Aix En Provence, France
[2] Inst Paoli Calmette, INSERM, UMR SE4S 912, F-13273 Marseille 09, France
来源
SCIENCES SOCIALES ET SANTE | 2012年 / 30卷 / 01期
关键词
TREATMENT DECISION-MAKING; MEDICAL UNCERTAINTY; WOMENS PERCEPTIONS; CHEMOTHERAPY; HEALTH; EXPERIENCE;
D O I
10.3917/sss.301.0047
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
One of the main tools available for making bio-medical decisions about the best treatment to prescribe is the risk-benefit ratio. This article takes a contextual approach to the decision-making processes involved in the prescription of adjuvant tamoxifen as a mean of reducing the risk of relapse of breast cancer. Using anthropological descriptive methods, it examines the discrepancy between patients' and doctors' perceptions of the risks and benefits of the treatment and analyses their underlying logics. Representations of women are related to cancer (fear of the disease), its treatment (efficacy) and tamoxifen (fear of hormones and aging), and can lead to a symbolic hierarchy of treatments, whereas doctors' professional practices focus mainly on the prevention of the recurrence of cancers.
引用
收藏
页码:47 / 71
页数:25
相关论文
共 50 条
  • [31] Influence of probenecid on endoxifen systemic exposure in breast cancer patients on adjuvant tamoxifen treatment
    Buck, Stefan A. J.
    Braal, C. Louwrens
    Hofman, Maaike M.
    Oomen-de Hoop, Esther
    de Bruijn, Peter
    Moghaddam-Helmantel, Inge M. Ghobadi
    Hussaarts, Koen G. A. M.
    Vastbinder, Mijntje B.
    Van Rossum-Schornagel, Quirine C.
    van Schaik, Ron H. N.
    Jager, Agnes
    Koolen, Stijn L. W.
    Mathijssen, Ron H. J.
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2022, 14
  • [32] Compliance with tamoxifen and arimidex in the adjuvant treatment of women with breast cancer
    Ziller, V.
    Holzhauer, W.
    Ziller, M.
    Wagner, U.
    Hadji, P.
    BREAST, 2007, 16 : S44 - S45
  • [33] Therapeutic drug monitoring of tamoxifen to improve adjuvant treatment of hormone sensitive breast cancer: The TOTAM study
    Braal, L.
    Jager, A.
    Lommen, K. M.
    Oomen-de Hoop, E.
    de Bruijn, P.
    Vastbinder, M. B.
    van Rossum-Schornagel, Q. C.
    Thijs-Visser, M. F.
    van Alphen, R.
    Struik, E. M.
    Zuetenhorst, J. M.
    Mathijssen, R. H.
    Koolen, S. L.
    ANNALS OF ONCOLOGY, 2020, 31 : S319 - S319
  • [34] Adjuvant Tamoxifen Influences the Lipid Profile in Breast Cancer Patients
    Lin, Che
    Chen, Li-Sheng
    Kuo, Shou-Jen
    Chen, Dar-Ren
    BREAST CARE, 2014, 9 (01) : 35 - 39
  • [35] ADJUVANT TAMOXIFEN IN BREAST-CANCER
    BLUM, JE
    LANCET, 1987, 2 (8561): : 747 - 747
  • [36] ADJUVANT TAMOXIFEN IN BREAST-CANCER
    JAKESZ, R
    LIPPMAN, ME
    CANCER TREATMENT REVIEWS, 1984, 11 (04) : 321 - 323
  • [37] Risk of endometrial cancer in breast cancer patients under long-term adjuvant treatment with tamoxifen
    Cecchini, S
    Ciatto, S
    Bonardi, R
    Mazzotta, A
    Pacini, P
    Muraca, MG
    Zappa, M
    TUMORI JOURNAL, 1998, 84 (01): : 21 - 23
  • [38] Tamoxifen in the adjuvant setting for breast cancer: Reflexions about the risk of uterine carcinosarcoma
    Leung, F.
    Terzibachian, J. -J.
    Govyadovskiy, A.
    Bourtembourg, A.
    Maillet, R.
    Riethmuller, D.
    GYNECOLOGIE OBSTETRIQUE & FERTILITE, 2009, 37 (05): : 447 - 451
  • [39] Tamoxifen-induced nonalcoholic steatohepatitis in breast cancer patients treated with adjuvant tamoxifen
    Nemoto, Y
    Saibara, T
    Ogawa, Y
    Zhang, T
    Xu, N
    Ono, M
    Akisawa, N
    Iwasaki, S
    Maeda, T
    Onishi, S
    INTERNAL MEDICINE, 2002, 41 (05) : 345 - 350
  • [40] Impact of CYP2D*6 in the adjuvant treatment of breast cancer patients with tamoxifen
    Markopoulos, Christos
    Kykalos, Stylianos
    Mantas, Dimitrios
    WORLD JOURNAL OF CLINICAL ONCOLOGY, 2014, 5 (03): : 374 - 381